Claude Haiku-5.5

Health systems deploy ambient AI scribes to draft clinical notes from patient encounters. Signals rising clinician reliance on unverified AI-generated documentation that requires new audit controls.

Writing · Concrete actor (hospital systems) and event (deploy AI). Lacks specific company/product names, dates, or numbers.

Hospitals report alert fatigue from predictive sepsis models generating false-positive escalations. Signals a need for validated thresholds and local performance monitoring before clinical reliance.

Judge · Multiple sources confirm hospitals experience alert fatigue from sepsis prediction models due to poor performance and high false-positive rates. Studies advocate for better validation and local monitoring.

Writing · Concrete actor (hospitals, clinicians), event (override rates), and quantitative anchor (85%).

Radiology departments deploy FDA-cleared imaging algorithms for triage of chest and stroke studies. Indicates governance gaps in local validation across scanner vendors and patient populations.

Judge · The need for local validation of FDA-cleared AI in radiology, especially across diverse data and populations, is well-documented, pointing to existing governance gaps.

Writing · Concrete actors (radiology departments, FDA), specific technologies (imaging algorithms, scanner vendors). Lacks quantitative/temporal anchor.

Clinical decision support tools now embed large language model outputs in electronic health record workflows. Signals shifting accountability for diagnostic suggestions from vendors toward treating clinicians.

Judge · The integration of LLMs in EHR CDS is occurring, and the debate around shifting accountability to clinicians is well-documented.

Writing · Concrete actor (vendors, clinicians), event (embed LLM outputs), temporal (now embed). Lacks quantitative anchor and active voice for 'signals shifting accountability'.

The EU AI Act classifies medical device AI as high-risk under its conformity assessment requirements. Signals overlapping obligations under the MDR and AI Act for hospital-deployed algorithms.

Judge · The EU AI Act classifies Medical Device AI as high-risk under specific conditions related to third-party conformity assessment under MDR/IVDR. This creates overlapping obligations.

Writing · Concrete actor, event, and anchor, but lacks a specific product/filing. Contains some generic forecast.

FDA authorizes AI-enabled devices with predetermined change control plans for post-market model updates. Signals that hospitals must track algorithm versions and validate each authorized modification locally.

Judge · The FDA's PCCP guidance details the necessity for manufacturers to specify and validate modifications, implying hospitals must track and potentially validate updates.

Writing · Concrete actor (FDA), event (finalizing framework), and measurable shift (new regulatory pathway) are present. Lacks a temporal anchor.

HHS rule under Section 1557 requires covered entities to mitigate discrimination risk in patient care decision support tools. Signals compliance obligations for hospital algorithm inventories and bias testing.

Judge · HHS Section 1557 final rule applies non-discrimination to AI/emerging tech in patient care decision support tools, requiring identification and mitigation of discrimination risks. Compliance starts July 2024 and May 2025.

Writing · Concrete actor (HHS), specific rule. Lacks quantitative/temporal anchor, uses 'mitigate risk' which is somewhat vague.

The EU AI Act phases in obligations for high-risk systems through 2026 and 2027. Indicates staggered compliance deadlines requiring hospitals to sequence AI procurement and governance investments.

Judge · The EU AI Act has a phased implementation. Rules for high-risk AI systems in Annex III apply from Dec 2027; those embedded in regulated products from Aug 2028.

Writing · Concrete actor, event, and anchor present. Some passive voice and generic 'postponement'.

Health systems negotiate indemnification and model-change notification terms in AI vendor contracts. Signals procurement teams shifting liability and audit rights into standard purchasing templates.

Judge · Health systems are actively negotiating AI-specific terms including liability and model-change notifications, seeking to shift risk and ensure transparency. [ebglaw.com](https://www.ebglaw.com/assets/htmldocuments/industries/artificial-intelligence/Health-Care-AI-Vendor-Agreements-Checklist-Epstein-Becker-Green.pdf), [foley.com](https://www.foley.com/insights/publications/2025/05/5-key-contracting-considerations-for-digital-health-companies-working-with-ai-ven/), [healthcarelawinsights.com](https://www.healthcarelawinsights.com/2026/05/ai-in-the-fine-print-why-your-contracts-may-not-be-ready/), [jaepperson.com](https://jaepperson.com/wp-content/uploads/2026/03/Governance_Brief_No_5_Vendor_Risk_Indem_Ins_Align_AI.pdf), [starbridge.ai](https://starbridge.ai/rfp/rfp-no-hhsc-25-005-healthcare-artificial-intelligence)

Writing · Concrete actors and event identified, but lacks temporal anchor and uses some implied language.

Clinicians use consumer generative AI tools for drafting messages and summarizing charts without enterprise approval. Signals gaps in data access controls and inventory visibility for IT governance teams.

Judge · Multiple sources confirm clinicians are using unauthorized AI for workflow efficiency, creating PHI exposure risks and highlighting governance gaps.

Writing · Concrete actor (clinicians), concrete event (use tools), measurable shift (drafting/summarizing). Lacks specific company/product names.

Health systems deploy AI tools faster than staff complete role-specific training and competency validation. Indicates operational risk from uneven oversight across clinical and administrative workflows.

Judge · Multiple sources confirm a significant gap between AI tool adoption and adequate, ongoing staff training/competency validation across healthcare systems.

Writing · Concrete actor (clinical staff), quantitative anchor (70%), and active voice. Lacks a specific company/project.

EU health data localization requirements constrain training pipelines for US-based AI vendors processing European patient records. Signals infrastructure redesign needs for cross-border model development and hosting.

Judge · EU regulations (GDPR, AI Act, EHDS, CADA) impose significant data residency and processing requirements for health data, making pooled global datasets for AI training problematic for US vendors.

Writing · Concrete actors (EU, US-based AI vendors), event (health data localization). Lacks quantitative/temporal anchor.

California law and EU guidance require patients to receive notice when generative AI drafts clinical communications. Signals disclosure workflows that patient-facing teams must operationalize within existing consent processes.

Judge · California law [leginfo.legislature.ca.gov] mandates disclosure for AI-drafted clinical communications starting Jan 1, 2025. EU guidance [rm.coe.int] emphasizes transparency, but without a specific law.

Writing · Names CA law and EU guidance. 'Must operationalize' is future-tense, and 'existing consent processes' lacks specificity.

Survey data indicate patients prefer clinician review over AI-only diagnostic decisions in primary care settings. Signals reputational exposure if AI-assisted diagnoses lack transparent physician accountability statements.

Judge · Multiple surveys (US, EU) show strong patient preference for human clinician oversight in AI diagnoses, and concern about lack of human interaction. This indicates reputational exposure.

Writing · Concrete actor (US patients), quantitative anchor (45%), active voice. 'Rises' is a vague quantifier.

Patient advocacy groups file complaints alleging racial bias in risk scores used for care management. Signals potential Office for Civil Rights scrutiny and reputational harm for network members.

Judge · The signal of algorithmic bias in risk scores and subsequent complaints by advocacy groups is well-documented, leading to regulatory scrutiny and potential reputational harm.

Writing · Names specific actors (advocacy groups, OCR) and a measurable event (complaints). 'Potential scrutiny' is a future-tense claim.

Patients and caregivers request plain-language explanations of how algorithms influenced their treatment plans. Indicates rising expectations for transparent, auditable AI decisions in patient portals and consent forms.

Judge · Patients consistently demand transparent, plain-language explanations of AI's influence on their care, often via consent forms and direct communication.

Writing · No concrete actor, event, or specific anchor. Uses 'increasingly' and generic forecast.